8.2.1. Cytotoxic medicines

Daunorubicin

- **Indication**: Myeloid leukaemia
- **ICD11 code**: 2C03.1
- **INN**: Daunorubicin
- **Medicine type**: Chemical agent
- **List type**: Complementary
- **Formulations**: Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)
- **EML status history**:
  - First added in 1999 (TRS 895)
  - Changed in 2002 (TRS 914)
  - Changed in 2007 (TRS 950)
  - Changed in 2015 (TRS 994)
  - Changed in 2023 (TRS 1049)
- **Sex**: All
- **Age**: Adolescents and adults
- **Therapeutic alternatives**: The recommendation is for this specific medicine
- **Patent information**: Patents have expired in most jurisdictions

**Tags**
- Cancer

**Wikipedia**
- Daunorubicin

**DrugBank**
- Daunorubicin

**Summary of evidence and Expert Committee recommendations**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of additional formulations of daunorubicin (injection 2 mg/mL and 5 mg/mL in vial and powder for injection 20 mg in vial) to the EML and EMLc.

[Read more about patents.](#)

[Expert Committee report](#)